Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on March 25, 2019. The report details a corporate action approved by the Board of Directors pursuant to stockholder authorization granted on June 26, 2018.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: The company implemented a 1-for-5 reverse stock split of its issued and outstanding common stock.
- Effective Date: The split became effective at 9:00 a.m. on March 26, 2019.
- Share Reclassification: Every five shares of issued common stock were reclassified into one share. No fractional shares were issued; instead, one whole share was issued in lieu of fractions.
- Equity Adjustments: Proportional adjustments were made to outstanding preferred shares, warrants, options, and other equity awards.
- Authorized Shares: The total number of authorized common shares remains at 160,000,000. The par value per share remains at $0.001.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the standard implementation of the reverse stock split. A press release regarding the split was issued on March 25, 2019, and is incorporated by reference.
Key Facts for Investor Verification
- Verify the post-split share count and price per share on the effective date of March 26, 2019.
- Confirm the adjusted terms of outstanding warrants, options, and preferred shares.
- Check the status of the Certificate of Amendment filed with the Delaware Secretary of State.
- Review the press release (Exhibit 99.1) for any additional context on the rationale for the split.